Table 1.

Summary of studies that evaluated the diagnostic potentials of BNP or NT-pro-BNP for LV disorders in CKDa

AuthorNo. of PatientsAUC for LVH, LVSDBest Cutoff for LVH and LVSD
Mallamaci et al.,33 2000212 HD and 34 PD0.81, 0.78LVH (BNP): 23.4 pmol/L (sens 62%, spec 88%, PPV 95%, NPV 61%)
LVSD (BNP): 38.9 pmol/L (sens 74%, spec 76%, PPV 31%, NPV 95%)
Mark et al.,42 200655 HD0.664, 0.532LVH (BNP): ND (sens 68%, spec 67%, PPV 79%, NPV 53%)
David et al.,46 200762 HDND, 0.95LVSD (BNP): ND (sens 94%, spec 21%, PPV 46%, NPV 83%)
deFilippi et al.,27 2005207 with stages 1 through 5 CKD0.73, ND (based on 99 patients)LVSD (NT-pro-BNP): 7168 pg/ml (sens 98%, spec 79%)
LVH (NT-pro-BNP): 271 pg/ml (sens 76%, spec 60%)
Khan et al.,28 200654 with CKD0.72, ND (NT-pro-BNP)LVH (NT-pro-BNP): 762 pg/ml (sens 63%, spec 67%, PPV 70%, NPV 57%)
0.72, ND (BNP)LVH (BNP): 200 pg/ml (sens 60%, spec 71%, PPV 72%, NPV 59%)
  • a AUC; area under the curve; LVH, left ventricular hypertrophy; LVSD, left ventricular systolic dysfunction; ND, not documented; NPV, negative predictive value; PPV, positive predictive value; sens, sensitivity; spec, specificity.